Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ DGKQ Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5101127
Description
Antibody detects endogenous levels of total DAGK.
Diacylglycerol (DAG) is a fundamental lipid second messenger that is produced in the nucleus. The accumulation of DAG in the nucleus is important for the regulation of cell growth and differentiation. Diacylglycerol kinases (DGKs) convert DAG to phosphatidic acid, thereby terminating diacylglycerol signaling, which results in the reduction of protein kinase C activity and cell cycle progression of T lymphocytes. Diacylglycerol kinases are divided into five subtypes, Type I-Type V. DGK-theta is a Type V DGK, and localizes mainly to the nucleus of various cell lines, such as MDA-MB-453, MCF-7, PC12 and HeLa. Nuclear DGK-theta co-localizes with phosphatidylinositol 4, 5-bisphosphate (PIP(2)). DGK-theta is the isoform responsive to alpha-Thrombin stimulation.
Specifications
DGKQ | |
Polyclonal | |
Unconjugated | |
DGKQ | |
110kDa; DAG kinase theta; DAGK; Dagk4; DAGK7; Dgk theta; Dgkd; DGKQ; DGK-theta; Diacylglycerol kinase theta; diacylglycerol kinase, delta (110 kDa); diacylglycerol kinase, theta; diacylglycerol kinase, theta 110kDa; diglyceride kinase theta; testis tissue sperm-binding protein Li 38a | |
Rabbit | |
Affinity chromatography | |
RUO | |
110524, 1609 | |
-20°C | |
Liquid |
Western Blot, Immunocytochemistry | |
1 mg/mL | |
PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 | |
P52824, Q6P5E8 | |
DGKQ | |
A synthesized peptide derived from human DGKQ(Accession P52824), corresponding to amino acid residues Q800-V850. | |
100 μL | |
Primary | |
Human, Mouse | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction